NCT02399592View on ClinicalTrials.gov

Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Ovarian Cancer
Interventions
DRUG

Bevacizumab

10 mg/kg q3w

DRUG

Tocotrinol

300 mg tid

Trial Locations (1)

DK-7100

Department of Oncology, Vejle Hospital, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT02399592 - Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter